NattoPharma

We are investing in clinical science to always be at the cutting edge on vitamin K2 research and hold an exclusive R&D alliance with VitaK BV, the world’s leading experts in research and scientific documentation of K vitamins.

NattoPharma is building competitive advantage through focus on IPR. We have granted patents and pending related to relevant indications and market segments, and will continue to develop our IPR portfolio to offer value for our customers in the health care, supplement and functional food markets.

Vitamin K2 is important for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. According to the World Health Organization (WHO) cardiovascular diseases and osteoporosis are the two biggest global health care problems. Osteoporosis is currently affecting some 200 million people globally, and 17 million people die of CVDs each year all over the world.

NattoPharma ASA was admitted to the Oslo Stock Exchange list "Oslo Axess" as per January 30th 2008.

About  MenaQ7®

MenaQ7® provides natural vitamin K2 (MK-7) as a fermentation extract whereby vitamin K2 is manufactured using Bacillus subtilis natto or Bacillus licheniformis. MK-7 is recognized in scientific literature for providingoptimal activity and vitamin K status in the body.

MenaQ7® is the best documented, commercially available natural Vitamin K2 with guaranteed actives and stability, clinical substantiation and international patents granted and pending.

For more information visit www.menaq7.com